- Home
- RILY vs PROK Comparison
RILY vs PROK Comparison
Compare RILY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILY
- PROK
- Stock Information
- Founded
- RILY 1973
- PROK 2015
- Country
- RILY United States
- PROK United States
- Employees
- RILY N/A
- PROK N/A
- Industry
- RILY Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RILY Finance
- PROK Health Care
- Exchange
- RILY Nasdaq
- PROK Nasdaq
- Market Cap
- RILY 185.4M
- PROK 220.6M
- IPO Year
- RILY 2007
- PROK N/A
- Fundamental
- Price
- RILY $5.05
- PROK $1.69
- Analyst Decision
- RILY
- PROK Buy
- Analyst Count
- RILY 0
- PROK 5
- Target Price
- RILY N/A
- PROK $4.50
- AVG Volume (30 Days)
- RILY 1.3M
- PROK 446.4K
- Earning Date
- RILY 12-03-2024
- PROK 11-12-2024
- Dividend Yield
- RILY 39.60%
- PROK N/A
- EPS Growth
- RILY N/A
- PROK N/A
- EPS
- RILY N/A
- PROK N/A
- Revenue
- RILY $1,221,832,000.00
- PROK N/A
- Revenue This Year
- RILY N/A
- PROK N/A
- Revenue Next Year
- RILY N/A
- PROK N/A
- P/E Ratio
- RILY N/A
- PROK N/A
- Revenue Growth
- RILY 19.73
- PROK N/A
- 52 Week Low
- RILY $4.07
- PROK $1.18
- 52 Week High
- RILY $40.09
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- RILY 46.55
- PROK 45.01
- Support Level
- RILY $4.52
- PROK $1.50
- Resistance Level
- RILY $4.93
- PROK $1.81
- Average True Range (ATR)
- RILY 0.34
- PROK 0.20
- MACD
- RILY -0.01
- PROK -0.02
- Stochastic Oscillator
- RILY 44.92
- PROK 24.84
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.